SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Dog (Bitcoin) is a fully decentralized memecoin on the Bitcoin blockchain, backed by a community dedicated to onboarding millions of people to Bitcoin.  Dog is secured by the Bitcoin blockchain and exists on Bitcoin L1, marking a significant innovation compared to Bitcoin with just BTC. Dog is a Bitcoin Runes token with a minimal on-chain footprint, native to Bitcoin, and stored in UTXOs, just like Bitcoin.   What is the project about?  Dog does not do any paid promotion and is fully decentralized just like Bitcoin. Every influencer who chooses to post about Dog either received the airdrop or bought on secondary. Dog leverages the CC0 license to ensure that Dog is not owned by any single entity but rather by everyone. This had lead to the "DOG Army" independently creating art, apps, lotteries, plushies, websites, podcast, magazines, X account, IRL meetups, clothing lines, PFP collections, Telegram groups, and TikTok/Instagram about Dog.  What makes your project unique?  Dog was airdropped in the fairest memecoin launch ever. In early 2024, the Bitcoin Ordinals ecosystem came together in a full volunteer initiative that rewarded early adopters of the Ordinals Protocol. There was no team allocation, and 100% of the supply was airdropped for free. The airdrop algorithm favored neither whales nor influencers; it was determined by the community and made open-source for maximum transparency.

Dog (Bitcoin)

$DOG.X is trending as a Bitcoin-native meme coin built on the Runes protocol, generating excitement for its fair launch and perceived potential to mirror $DOGE.X's success. The community emphasizes its strong connection to the Bitcoin blockchain, arguing it offers enhanced security and utility compared to meme coins on other networks. Discussions also highlight the growing #DOGArmy and anticipation for broader exchange listings.

Hedera is a decentralized public network where developers can build secure, fair applications with near real-time consensus. The platform is owned and governed by a council of global innovators including Avery Dennison, Boeing, Deutsche Telekom, DLA Piper, FIS (WorldPay), Google, IBM, LG Electronics, Magalu, Nomura, Swirlds, Tata Communications, University College London (UCL), Wipro, and Zain Group.   The Hedera Consensus Service (HCS) acts as a trust layer for any application or permissioned network and allows for the creation of an immutable and verifiable log of messages. Application messages are submitted to the Hedera network for consensus, given a trusted timestamp, and fairly ordered. Use HCS to track assets across a supply chain, create auditable logs of events in an advertising platform, or even use it as a decentralized ordering service.

Hedera Hashgraph

Hedera Hashgraph is trending as the community discusses potential catalysts including a spot ETF and the Market Clarity Act. Many are expressing bullish sentiment and accumulating HBAR, while also highlighting its real-world use cases and institutional partnerships. Mentions of Hedera's meme coin $GIB.X are also contributing to the increased attention.

Pyth Network is a decentralised oracle network designed to provide real-time financial market data to decentralised applications (dApps) across multiple blockchains. It allows developer to secure smart contracts with reliable, low-latency market data from institutional sources, and build apps with high-fidelity oracle feeds designed for mission-critical systems.

Pyth Network

Pyth Network is trending as the U.S. Department of Commerce has selected it to verify and distribute economic data onchain, marking a significant step in the adoption of decentralized infrastructure. The community sees this as a major validation of Pyth's role as a trusted data source and anticipates further expansion of its data offerings. Discussions revolve around potential price targets and the impact of institutional adoption on the broader crypto market.

Lucid Group, Inc. manufactures electric vehicles. It designs, develops, and builds energy storage systems for electric vehicles and supplies automakers with the battery pack system needed to power hybrid, plug-in, and electric vehicles. The company was founded in December 2007 and is headquartered in Newark, CA.

Lucid Group Inc

Lucid Group is trending due to discussions around high short interest, the cost to borrow shares, and potential for a short squeeze following its recent reverse stock split. Community members are debating the impact of the split on the stock's price and future, with some expressing concern over potential dilution and others pointing to the company's technology and Saudi backing as reasons for optimism. Recent news highlights include the CEO's rebuttal of third-party sales data and the closing of a $300 million investment from Uber.

Scilex Holding Co. engages in the acquisition, development, and commercialization of non-opioid pain management products for the treatment of acute and chronic pain. Its products include ZTLido, Elyxyb, and Gloperba. The company was founded on February 21, 2020 and is headquartered in Palo Alto, CA.

Scilex Holding Company

SCLX is trending as investors discuss the potential impact of the upcoming Semnur merger vote and the possibility of a dividend payout. The community is actively debating the company's strategic moves, particularly in relation to short sellers, and anticipating a potential short squeeze. Discussions also include Scilex's relationship with Sorrento and the potential for a combined buyout.

Samsara, Inc. develops internet connected sensor systems. It combines plug-and-play sensors, wireless connectivity, and cloud-hosted software integrated for deployment. The company was founded by John Bicket and Sanjit Biswas in 2015 and is headquartered in San Francisco, CA.

Samsara Inc - Ordinary Shares - Class A

Samsara Inc

Samsara ($IOT) is trending following a positive earnings report, driving discussions around the company's growth and future potential. Community members are analyzing analyst ratings and price target adjustments, while also weighing in on the impact of new partnerships and product innovations. Some traders are monitoring insider selling, and the overall impact of recent institutional activity.

ASML Holding NV engages in the development, production, marketing, sales, upgrading and servicing of advanced semiconductor equipment systems. It includes lithography, metrology and inspection systems. The company was founded on April 1, 1984 and is headquartered in Veldhoven, the Netherlands.

ASML Holding NV - New York Shares

ASML Holding NV

ASML is trending due to an upgrade from UBS to a buy rating, citing long-term growth drivers and potential upside. Community discussions revolve around the stock's disconnect from other semi plays like AMD and NVDA, with some viewing it as an underrated buy-and-hold opportunity. Despite some analyst caution around 2026, the broader sentiment remains optimistic, especially regarding the company's unique position in lithography.

ViaSat, Inc. engages in providing communications technologies and services. It operates through the Communication Services and Defense and Advanced Technologies business segments. The Communication Services business segment provides a wide range of broadband and narrowband communications solutions across government and commercial mobility markets. The Defense and Advanced Technologies business segment develops and offers a diverse array of resilient, vertically integrated solutions to government and commercial customers, leveraging the company’s technical competencies in encryption, cyber security, tactical gateways, modems, and waveforms. The company was founded by Mark D. Dankberg and Mark J. Miller on May 1, 1986 and is headquartered in Carlsbad, CA.

Viasat, Inc.

Viasat ($VSAT) is trending due to recent news, potentially fueled by an upcoming earnings call. Community members are actively debating the stock's prospects and valuation, with some pointing to substantial government contracts and potential value unlocking opportunities while others express concerns about debt and historical performance. Discussions also involve comparisons to competitors like AST SpaceMobile and Starlink, alongside speculation on potential short squeezes.

Cidara Therapeutics, Inc. is a biotechnology company, which engages in the discovery, development, and commercialization of therapeutics for patients facing serious diseases, specifically oncology and infectious diseases. Its product pipeline includes Rezafungin Acetate and Cloudbreak. The company was founded by Kevin M. Forrest, Kevin J. Judice, and H. Shaw Warren in December 2012 and is headquartered in San Diego, CA.

Cidara Therapeutics Inc

Cidara Therapeutics is trending as investors discuss the potential of its universal flu protection, CD388, following positive Phase 2b trial results. Community talking points include speculation around upcoming milestones like FDA decisions and BARDA funding, as well as potential buyout scenarios given the strong data and market opportunity. Some traders are also eyeing technical indicators, noting accumulation patterns and potential for a breakout, while others discuss the impact of a potential share offering.

Celcuity, Inc. operates as a cellular analysis company. The company discovers new cancer sub-types and commercializing diagnostic tests designed to improve the clinical outcomes of cancer patients treated with targeted therapies. The firm's proprietary CELx diagnostic platform is the commercially ready technology that uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the targeted therapy that treats it. The company was founded by Brian F. Sullivan and Lance G. Laing in January 2012 and is headquartered in Minneapolis, MN.

Celcuity Inc

CELC is trending after announcing positive Phase 3 trial results for its breast cancer therapy, showing significant reduction in disease progression. The community is buzzing with speculation about FDA approval and potential M&A activity, driving the stock to new highs. Traders are weighing the potential for continued gains against concerns of a possible offering.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Bausch + Lomb (BLCO) Reports Q2 Earnings: What Key Metrics Have to Say

Although the revenue and EPS for Bausch + Lomb (BLCO) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Bausch + Lomb (BLCO) Q2 Earnings and Revenues Surpass Estimates

Bausch + Lomb (BLCO) delivered earnings and revenue surprises of +16.67% and +2.37%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

New Strong Sell Stocks for July 30th

ACHC, BLCO and BBCP have been added to the Zacks Rank #5 (Strong Sell) List on July 30, 2025.

New Strong Sell Stocks for July 24th

COMP, EKTAY and BLCO have been added to the Zacks Rank #5 (Strong Sell) List on July 24, 2025.

Analysts Estimate Bausch + Lomb (BLCO) to Report a Decline in Earnings: What to Look Out for

Bausch + Lomb (BLCO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

WF downgrades Bausch + Lomb on enVista recall giving a near-term uncertainty

Investing.com -- Wells Fargo downgraded Bausch + Lomb Corp to Equal Weight from Overweight on uncertainty from the voluntary recall of its enVista intraocular lenses (IOLs), which is expected to weigh on sales growth, earnings, and investor sentiment. Brokerage cut its price target to $15 from $24, based on 9.5x its 2026 EBITDA estimate of $1.0 billion.

Bausch Health Companies Inc. shares (BHC) jumped over 7% in after-hours trading on Wednesday following a solid fourth-quarter earnings report that beat revenue estimates and reaffirmed strong guidance for 2025.The company posted Q4 revenue of $2.56 billion, surpassing the consensus estimate of $2.51 billion, while adjusted earnings per share (EPS) of $1.14 narrowly topped expectations of $1.13.&nbsp;Adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) came in at $935 million, up from $869 million a year ago.CEO Thomas Appio highlighted 2024 as a year of "delivering on our commitments," with results landing at the high end of revenue guidance and exceeding expectations for adjusted EBITDA (excluding Bausch + Lomb) and operating cash flow.Salix, the company's gastrointestinal and hepatology division, generated $634 million in Q4 revenue, up 9% year-over-year. This was largely driven by Xifaxan, a treatment for irritable bowel syndrome and traveler's diarrhea, which posted 16% growth.&nbsp;The Solta segment, which includes medical aesthetics, saw Q4 revenue climb 34% to $138 million, fueled by strong demand in South Korea and China.For 2025, Bausch Health projects revenue between $9.90 billion and $10.15 billion, above the consensus estimate of $9.89 billion.&nbsp;The company also forecasts FY25 adjusted EBITDA between $3.525 billion and $3.675 billion.<figure class="image"><img style="aspect-ratio:1318/324;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/BHC_sentiment_and_message_volume_Feb_19_07562dbe77.png" alt="BHC sentiment and message volume Feb 19.png" width="1318" height="324"><figcaption>BHC sentiment and message volume Feb 19 | source: Stocktwits</figcaption></figure>Retail sentiment on Stocktwits turned 'extremely bullish' following the earnings report, with message volume spiking 1,900% on Wednesday.One user highlighted "very good organic revenue growth and solid guidance," expecting a strong bounce for the stock.&nbsp;Another hoped for a rally past $20 per share.<stembedurl>https://stocktwits.com/Neildc/message/604885428</stembedurl><stembedurl>https://stocktwits.com/Maxgluteal/message/604910108</stembedurl>However, BHC shares remain about 35% below analysts' average target price of $8.83.&nbsp;The stock has lost over 19% year-to-date.&nbsp;&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.

Bausch Health Stock Pops After-Hours On Q4 Earnings Beat, Bullish Outlook: Retail Confidence Rises

The company’s Solta segment, which includes medical aesthetics, saw Q4 revenue climb 34% to $138 million, fueled by strong demand in South Korea and China.

Equity

Bausch & Lomb to shake up contact lenses with deal off the table

Bausch & Lomb said this month it had explored taking the company private with a third-party buyer. No deal was reached as a consortium of private equity firms TPG and Blackstone reportedly backed...

Bausch + Lomb Announces Fourth-Quarter and Full-Year 2024 Results, Provides 2025 Guidance

Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced its fourth-quarter and full-year 2024 financial...

Bausch + Lomb Provides Update on Potential Sale

Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, issued the following update on a potential sale, which was...

Bausch + Lomb Corp. develops, manufactures, and markets eye health products. It offers over-the-counter supplements, eye care products, ophthalmic pharmaceuticals, contact lenses, lens care, ophthalmic surgical devices, and instruments. The company operates its business through three segments: Vision Care/Consumer Health Care, Ophthalmic Pharmaceuticals and Surgical. The Vision Care/Consumer Health Care segment includes both contact lens and consumer eye care businesses. The Ophthalmic Pharmaceuticals segment consists of a broad line of proprietary pharmaceutical products for post-operative treatments and treatments for a number of eye conditions, such as glaucoma, eye inflammation, ocular hypertension, dry eyes and retinal diseases. The Surgical segment consists of medical device equipment, consumables and instrumental tools and technologies for the treatment of corneal, cataracts, and vitreous and retinal eye conditions, and includes IOLs and delivery systems, phacoemulsification equipment and other surgical instruments and devices necessary for cataract surgery. Bausch + Lomb was founded by John Jacob Bausch and Henry Lomb in 1853 and is headquartered in Vaughan, Canada.

BLCO
Bausch + Lomb Corp.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest BLCO News

BLCO Bausch + Lomb Corp.